Sergei Gryaznov
Direttore Tecnico/Scientifico/R&S presso MAIA BIOTECHNOLOGY, INC.
Patrimonio netto: 211 427 $ in data 31/05/2024
Profilo
Sergei M.
Gryaznov is the founder of Lynx Therapeutics, Inc. (founded in 1993).
He is currently the Chief Scientific Officer at MAIA Biotechnology, Inc. (since 2019).
Dr. Gryaznov previously worked as the Chemistry Director at Geron Corp.
(from 1998 to 2013) and as the Chief Technology Officer at Exicure Operating Co. Dr. Gryaznov holds graduate and doctorate degrees from Moscow State University Lomonosov.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
MAIA BIOTECHNOLOGY, INC.
0.20% | 26/04/2024 | 44 511 ( 0.20% ) | 211 427 $ | 31/05/2024 |
Posizioni attive di Sergei Gryaznov
| Società | Posizione | Inizio |
|---|---|---|
| MAIA BIOTECHNOLOGY, INC. | Direttore Tecnico/Scientifico/R&S | 01/12/2019 |
Precedenti posizioni note di Sergei Gryaznov
| Società | Posizione | Fine |
|---|---|---|
| GERON CORPORATION | Corporate Officer/Principal | 01/01/2013 |
Lynx Therapeutics, Inc.
 Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Corporate Officer/Principal | 01/01/1997 |
Exicure Operating Co.
 Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Sergei Gryaznov
| Moscow State University Lomonosov | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GERON CORPORATION | Health Technology |
| Aziende private | 3 |
|---|---|
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Health Technology |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Health Technology |
| MAIA Biotechnology, Inc. |
- Borsa valori
- Insiders
- Sergei Gryaznov
